🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Elevate Now raises Rs 18 Cr in seed round led by Physis Capital

EntrackrEntrackr · 16h ago
Elevate Now raises Rs 18 Cr in seed round led by Physis Capital
Medial

Snippets Elevate Now raises Rs 18 Cr in seed round led by Physis Capital Elevate Now, a doctor-led, root-cause-driven clinical weight loss platform, has raised Rs 18 crore in a seed funding round led by Physis Capital along with participation from Inflection Point Ventures and Titan Capital. The Bengaluru-based startup had earlier secured $2 million in a pre-seed funding round from W Health Ventures, Narayana Health, and Swiggy Co-founder Sriharsha Majety. The proceeds will be deployed towards strengthening its technology platform, expanding proprietary clinical research, developing medicinal and nutritional supplements, and building next-generation personalisation systems to improve outcomes at scale, Elevate Now said in a press release. Launched in November 2022 by Suryansh Kumar, Elevate Now is a clinical weight loss company that focuses on pioneering non-surgical, medical weight loss solutions. The startup offers personalized, science-based weight management programmes designed to help individuals achieve their fitness goals in a sustainable and responsible manner. According to Elevate Now, it works on diagnosing underlying drivers for weight gain such as insulin resistance, inflammation and hormonal imbalances, and then delivering personalised treatment under medical supervision rather than generic calorie restriction. The platform operates a fully online, subscription-based model offering programs ranging from 3 to 24 months. Each user is assigned a physician trained in obesity medicine, supported by blood diagnostics, continuous glucose monitoring data and a dedicated health coach. Elevate Now claims to have onboarded over 30,000 paying users to date and users have recorded an average weight loss of approximately 10 kilograms over six months. Between April 2025 and January 2026, it reported average month on month revenue growth of 17%. It competes with the other notable players in this segment such as Healthifyme, Sugarfit, Fittr, amongst others.

MedySeva raises Rs 4 Cr led by Unicorn India Ventures

EntrackrEntrackr · 3m ago
MedySeva raises Rs 4 Cr led by Unicorn India Ventures
Medial

Healthtech startup MedySeva has raised Rs 4 crore in a seed round led by Unicorn India Ventures. The proceeds will be used to expand phygital healthcare clinics across tier-II and tier-III locations, upgrade its telemedicine platform, strengthen digital infrastructure, increase patient outreach, and build on-ground operations and clinical support teams. Founded in 2022 by Dr. Vishesh Kasliwal, MedySeva provides teleconsultation and in-person doctor services through a hybrid healthcare model for rural and semi-urban regions. The company connects patients to doctors across medical specialities using a central telemedicine platform supported by physical clinics. MedySeva claims to have delivered 1,00,000 consultations in the last 12 months with a 60% repeat-patient rate. The firm aims to scale to 2 lakh annual consultations in 18 months. It has partnered with medical colleges to set up satellite clinics and onboarded doctors from 10 medical specialties. The brand has also tied up with pharmacies and healthcare providers to build a local care network. MedySeva plans to open over 500 phygital healthcare centres across India over the next 18–24 months and enter five new states through institutional and state-level partnerships. MedySeva competes with primary healthcare and telemedicine players such as Practo, Medibuddy, Clinikk, HealthPlix, CureBay, and eSanjeevani in rural and semi-urban healthcare access.

MiClient raises seed round from IAN Group, others

EntrackrEntrackr · 1y ago
MiClient raises seed round from IAN Group, others
Medial

MiClient, an AI-driven B2B sales enablement platform, has raised Rs 3.9 crore in its seed funding round led by IAN Group with participation from Anicut, GSF, RTAF, and Keiretsu. Vikas Kuthiala and Pratik Mathurkar from IAN led the round. The round follows an initial pre-seed investment in October 2023 from 100x.VC. The proceeds will be used to build a stronger team and expand market presence across more geographies in India. In addition to market expansion, MiClient is developing an AI-based model to create quotations and invoices in seconds, further streamlining the sales process for its users. Led by Swati Sharma, MiClient’s easy-to-use CPQ platform helps sales teams close deals three times faster, with the average deal now closing in just 10 days. Expanding further into India’s industrial hubs, MiClient is executing a feet-on-the-street go-to-market strategy. MiClient is expanding into more industrial hubs across India using a direct sales approach. With over 150 customers and over 1,500 users, the company serves SMEs, particularly in the B2B manufacturing sector, with a user-friendly platform.

Oncology startup 4baseCare raises Rs 90 Cr led by Ashish Kacholia and Lashit Sanghvi

EntrackrEntrackr · 13d ago
Oncology startup 4baseCare raises Rs 90 Cr led by Ashish Kacholia and Lashit Sanghvi
Medial

Precision oncology startup 4baseCare has raised Rs 90 crore ($9.8 million) in the first close of its Series B round co-led by Ashish Kacholia and Lashit Sanghvi, with participation from existing investor Yali Capital. The new round comes after a gap of two years. In 2024, the company had raised $6 million in Series A funding, led by Yali Capital, with participation from Infosys. The fresh capital will be used to expand 4baseCare’s hospital-linked genomics lab network across India, the Middle East, Southeast Asia, Latin America, and Central Asia. It will also scale its AI-powered precision oncology platform, OncoTwin, which supports clinical decision-making for cancer treatment. Founded by Hitesh Goswami, 4baseCare focuses on building population-relevant clinico-genomic datasets to improve cancer diagnosis and treatment outcomes in underrepresented populations. Its platform integrates genomic testing with real-world clinical and outcomes data to generate actionable insights for oncologists. The OncoTwin platform was recently selected for the MSK iHub program at Memorial Sloan Kettering Cancer Center, New York. The company works closely with hospitals to offer genomics-led cancer diagnostics within clinical settings and is positioning itself to scale across emerging markets. Investor interest in cancer-focused startups has picked up in recent years. Last year, Everhope Oncology raised $10 million in seed funding, and MOC Cancer Care & Research Centre secured $18 million led by Elevation Capital. ErlySign, OnCare, and OneCell Diagnostics are also among the funded startups.

Gen AI startup KonProz raises $700K

EntrackrEntrackr · 1y ago
Gen AI startup KonProz raises $700K
Medial

KonProz, a generative artificial intelligence (GenAI) startup, has raised $700,000 in a new round led by Dr. Ruchi Parekh, RDB Group and angel investors. The proceeds will be used for building a Generative AI intellectual property for the legal domain, team expansion and scaling operations to broaden KonProz’s platform capabilities. Founded by Piyush Chopra and Shiladitya Dash, KonProz leverages emerging technologies such as GenAI to build SaaS solutions for the legal, tax and regulatory space. Since its inception, KonProz claims to have received significant attention for its flagship product, KonProz GPT, the first GenAI tool trained specifically on India’s tax, legal and regulatory laws. Since the release of its phase 1 product in November 2023, KonProz has over 2,000 active users including senior professionals from the Big4s and Tier 1 law firms, and aims to now build a comprehensive suite of products. In the past six months, generative AI platforms have managed to score decent funding in their early stages. In December 2023, Sarvam AI raised $41 million in a Series A round led by Lightspeed while Ema scooped up $25 million which is the second largest funding in this space. Neysa bagged $20 million in Series A while Vodex raised $2 million in its seed round.

Praan Health raises 8.5 Cr in seed round led by Rainmatter Investments

EntrackrEntrackr · 3m ago
Praan Health raises 8.5 Cr in seed round led by Rainmatter Investments
Medial

Praan Health, a lifestyle-first chronic care platform for parents aged 50 and above, has raised Rs 8.5 crore in a seed funding round led by Rainmatter Investments with participation from WEH Ventures and angel investors, including Alakh Pandey and Prateek Maheshwari (PhysicsWallah) and Arjun Vaidya, among others. The proceeds will be utilized to strengthen its product and technology capabilities, expand its clinical and coaching teams, and expand its service delivery across India, Praan Health said in a press release. Launched in 2024 by Navneeth Ramprasad, Praan Health is a lifestyle-first chronic care platform designed to help parents live longer, stronger, and pain-free lives. The startup combines physician-led care, clinical nutrition, and strength training to reverse and manage chronic conditions through habit transformation — not hospital dependence. According to the Bengaluru-based startup, it has recently launched its mobile app, a one-stop platform that allows young adults to manage their parents’ health journeys, from blood test uploads and risk scores to weekly progress updates and doctor consultations. Using an integrated approach that combines physician supervision, clinical nutrition and one-on-one strength training, Praan delivers personalized 90/180/365-day programmes for more than 25 chronic conditions, including diabetes, hypertension, arthritis, osteoporosis and post-surgery recovery. In less than a year, Praan claims to have supported over 1,500 families across India through over 50,000 personalized sessions, led by a multidisciplinary team of physicians, clinical nutritionists, physiotherapists, and strength coaches. The company aspires to redefine chronic care in India — from frailty and dependence to strength, vitality, and independence.

Biotech startup Exsure raises seed round led by Unicorn India Ventures

EntrackrEntrackr · 1y ago
Biotech startup Exsure raises seed round led by Unicorn India Ventures
Medial

Biotech startup Exsure has raised Rs 3 crore in a seed round led by Unicorn India Ventures. The fresh funds will be used to complete the non-clinical study of its exosome-based drug delivery platform, support its global expansion plans with in-house manufactured R&D products, and promote its offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries, the company said in a press release. Co-founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup focused on reducing the side effects and toxicity of anti-cancer drugs through its patented exosomal drug-delivery platform that targets both cancer and cancer stem cells. With its cutting-edge technology, the company aims to minimize the toxic effects of chemotherapy and reduce the likelihood of cancer relapse, thereby improving the quality of life for cancer patients. Over the past 12 months, Exsure has initiated a non-clinical study in India in collaboration with a CRO and completed preclinical studies using its patented technology. The company has launched its first in-house manufactured products and gained collaborators and partners across India for its products and services. According to market research, the Indian biotechnology industry is expected to reach $150 billion by 2025 and has the potential to grow to $270–300 billion by 2030. The Bhubaneswar-based company reported fivefold growth in the last fiscal year and is on track to service more than 50 clients this year with its R&D products, including Exosure (a 3-in-1 exosome isolation reagent), Leucosure (a PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent). Additionally, the company has been selected for the OIST Innovation Accelerator Program in Japan to support its business expansion and conduct clinical trials.

Download the medial app to read full posts, comements and news.